Opioid Overdose Clinical Trial
Official title:
Developing and Testing the Opioid Rapid Response System
NCT number | NCT06238128 |
Other study ID # | 2097714 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 24, 2024 |
Est. completion date | July 31, 2025 |
The pervasive impact of the opioid epidemic has touched all layers of society for the past two decades, resulting in over 115 deaths daily and imposing annual costs of $78.5 billion. Responding swiftly to overdoses, akin to various medical emergencies, poses a significant challenge, particularly in geographically dispersed rural areas and densely populated urban settings. Effectively delivering the life-saving drug naloxone, which counteracts the effects of overdoses, necessitates a well-coordinated and cost-efficient response system. Simply opting for widespread distribution of naloxone, even with citizen involvement, proves to be a financially burdensome approach when compared to more targeted strategies. Moreover, obstacles such as limited access, inadequate or unavailable naloxone training, and delayed response times from emergency responders compound the problem. Addressing these issues, the proposed Opioid Rapid Response System (ORRS) project seeks to advance prevention science by adopting an innovative approach that incorporates technology and contemporary communication theory. The primary objective of the ORRS project is to mitigate opioid overdose deaths by enlisting and training citizens to administer naloxone in response to such events. Leveraging the PulsePoint health app, which connects citizens to cardiac events, the ORRS project will extend its capabilities to respond to overdose incidents. This initiative involves comprehensive development of ORRS, followed by a randomized clinical trial on a national scale to assess its effectiveness. The study aims to contribute to both prevention and implementation science by identifying optimal recruitment strategies and testing a model of online training. In pursuit of these objectives, the study is guided by the following Specific Aims: SA 1: Refine and complete the development of ORRS. SA 2: Conduct a randomized clinical trial to evaluate the effectiveness of the intervention. SA 3: Prepare ORRS for dissemination.
Status | Recruiting |
Enrollment | 1600 |
Est. completion date | July 31, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Citizens who live in participating PulsePoint communities - Must to be 18 and older - Must be fluent in English - Must have access to the mobile data and able to download and use apps in a smartphone Exclusion Criteria: - Citizens who do not live in participating PulsePoint communities - Under 18-year-old - Citizens who are not fluent in English - Citizens who do not have access to mobile data and unable to download and use apps in a smartphone. |
Country | Name | City | State |
---|---|---|---|
United States | Ewald & Wasserman Research Consultants, LLC | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of Missouri-Columbia |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Knowledge of overdose sign | Investigators will use a subset of Opioid Overdose Knowledge Scale (OOKS) to measure through a forced choice scale with each choice coded as correct (=1) or incorrect (=0). Higher score indicated greater knowledge of overdose sign. | up to 24 hours | |
Primary | Knowledge of overdose management | Investigators will use a subset of Opioid Overdose Knowledge Scale (OOKS) to measure through a forced choice scale with each choice coded as correct (=1) or incorrect (=0). Higher score indicated greater knowledge of overdose management. | up to 24 hours | |
Primary | Self-Efficacy toward intervening opioid overdose | Investigators will modify self-efficacy scale developed and theorized by Bandura (2005). Response options are from 0 (no confident) to 100 (highly confident). Higher score indicates greater self-efficacy | up to 24 hours | |
Primary | Response efficacy about intervening opioid overdose | Investigators will develop and measure how participants perceive the effectiveness of activities to intervene opioid overdose events in communities. Response options are from 0 (not effective) to 100 (highly effective). Higher score indicate greater response efficacy. | up to 24 hours | |
Primary | Concerns related to overdose management | Investigators will use a subset of Opioid Overdose Attitude Scale (OOAS) with 5 point scale (1: strongly disagree ~5: strongly agree). Higher score indicates the greater concerns. | up to 24 hours | |
Primary | Intent to intervene opioid overdose events in communities | Investigators will use behavioral intention scale developed by in the opioid training literature (Hecht et al., 2023) to measure intent to intervene opioid overdose events in communities (e.g., administering Narcan). Response options are from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicates grater intention to intervene opioid overdose events in communities. | up to 1 month | |
Primary | The number of days per week, on average, to carry Narcan | Single item: how many days per week, on average, participants carry Narcn | Up to 6 months | |
Primary | Number of Participants to response to overdose events from PulsePoint app. | Single item: whether participant response to overdose events from PulsePoint notifications/alerts | Up to 6 months | |
Primary | Number of participants to administer Narcan | Single item: Whether participant administer Narcan to respond opioid overdose events in communities. | Up to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04372238 -
The Rhode Island Prescription and Illicit Drug Study
|
N/A | |
Recruiting |
NCT03924505 -
Preventing Opioid Overdose Mortality in the United States
|
N/A | |
Completed |
NCT05093309 -
Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone
|
N/A | |
Completed |
NCT05219669 -
Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
|
Phase 1 | |
Completed |
NCT04317053 -
Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
|
Phase 3 | |
Not yet recruiting |
NCT06466005 -
UnityPhilly Response App for Overdose Reversal
|
||
Recruiting |
NCT04815590 -
Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
|
||
Active, not recruiting |
NCT05096429 -
Preventing Overdose Using Information and Data From the Environment
|
N/A | |
Suspended |
NCT05114460 -
Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal
|
Phase 2 | |
Completed |
NCT02662153 -
Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
|
||
Active, not recruiting |
NCT05944133 -
Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
|
||
Completed |
NCT05377255 -
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
|
Phase 1 | |
Recruiting |
NCT05877118 -
Improving Availability of Intranasal Naloxone
|
N/A | |
Recruiting |
NCT05072249 -
European Cohort Study of the Effectiveness of Take Home Naloxone
|
||
Withdrawn |
NCT05808881 -
Clinical Outcomes From Nalmefene
|
Phase 4 | |
Not yet recruiting |
NCT01622504 -
Naloxone Nasal Spray Pharmacokinetic Study
|
Phase 1 | |
Not yet recruiting |
NCT06429436 -
Vending Machine Naloxone Distribution for Your Community (VENDY)
|
Phase 4 | |
Completed |
NCT05506267 -
Development of a Tracheal Sound Sensor
|
||
Completed |
NCT02535494 -
Risks and Benefits of Naloxone Prescribing
|
N/A | |
Not yet recruiting |
NCT06408714 -
Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose
|
Phase 3 |